AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 24853809
Drug: Insulin only
RxNorm normalized name: Isophane insulin only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin only (32%)
Trial: 24853809
Drug: Insulin and
RxNorm normalized name: Isophane insulin and porcine regular insulin only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin and oral antidiabetics (OADs) (15%)
Trial: 24853809
Drug: No drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No drugs (26%)
Trial: 23011325
Drug: Calcium‐containing preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium‐containing preparation administrated orally for 1 to 3 months
Trial: 20498618
Drug: Valsartan/hydrochlorothiazide (320/25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valsartan/hydrochlorothiazide (320/25 mg)
Trial: 20498618
Drug: Hydrochlorothiazide plus
RxNorm normalized name: hydralazine hydrochloride / hydrochlorothiazide Oral Capsule [Hydralazine Plus]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide plus amlodipine (25 mg and 10 mg)
Trial: 18677236
Drug: Moderate viscosity
RxNorm normalized name: polyethylene terephthalate (intrinsic viscosity 0.40-0.70)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate viscosity hydroxypropylmethylcellulose-containing formulation
Trial: 10100273
Drug: Liposomal daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liposomal daunorubicin (DaunoXome) - 60 mg/m2, intravenous infusion, once every 4 weeks, up to 600 mg/m2 cumulative dose
Trial: 1672392
Drug: Intramuscular magnesium
RxNorm normalized name: intramuscular immunoglobulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular magnesium sulphate every week for 6 weeks
Trial: 6512802
Drug: Intravenous Augmentin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous Augmentin (amoxycillin and clavulanic acid)
Trial: 30475777
Drug: Esophageal pressure
RxNorm normalized name: Cellspan Esophageal Implant
DrugBank: Cellspan Esophageal Implant (DB18688)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esophageal pressure titration PEEP (n = 12)
Trial: 30475777
Drug: ARDSNet (PEEP-FiO2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ARDSNet (PEEP-FiO2 table) titration PEEP (n = 11)
Trial: 29480843
Drug: Early rehabilitation
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early rehabilitation therapy
Trial: 26973269
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (rehabilitation therapy after leaving ICU)
Trial: 24738933
Drug: Vitamin B1
RxNorm normalized name: Vitamin B1
DrugBank: Monophosphothiamine (DB16023)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin B1 100 mg daily for three months
Trial: 22343669
Drug: Parenteral nutrition
RxNorm normalized name: parenteral nutrition solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral nutrition (PN) during HSCT
Trial: 15257032
Drug: FK778 high-level
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FK778 high-level group (2 x 600 mg/day FK778 followed by 150 mg/day)
Trial: 15257032
Drug: FK778 low-level
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: FK778 low-level group (1 x 600 mg/day FK778 followed by 75 mg/day)
Trial: 15257032
Drug: FK778 treatment
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: FK778 treatment
Trial: 9851959
Drug: Clomipramine (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clomipramine (25 mg administered intravenously)
Trial: 2692315
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg ASS daily
Trial: 2692315
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg ASS daily
Trial: 31284771
Drug: Mirogabalin 15
RxNorm normalized name: mirogabalin
DrugBank: Mirogabalin (DB11825)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Mirogabalin 15 mg twice daily
Trial: 31722446
Drug: Mirogabalin 10
RxNorm normalized name: mirogabalin
DrugBank: Mirogabalin (DB11825)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Mirogabalin 10 or 15 mg twice daily
Trial: 31004141
Drug: Standard of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care (SOC) plus 48-hour positive airway pressure (PAP) therapy
Trial: 20920136
Drug: Spray catheter
RxNorm normalized name: CATHETER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spray catheter instillation
Trial: 20920136
Drug: Standard injection
RxNorm normalized name: Stangard
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard injection through the working channel
Trial: 10613619
Drug: Acetaminophen plus
RxNorm normalized name: acetaminophen / hydrocodone Oral Capsule [Ceta Plus]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen plus codeine
Trial: 9605375
Drug: Oxycodone 30
RxNorm normalized name: oxycodone 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxycodone 30 microg/kg
Trial: 9605375
Drug: Morphine 45
RxNorm normalized name: morphine 45 mg/24 hours oral capsule, extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine 45 microg/kg
Trial: 8091435
Drug: High plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High plasma levels of homocyst(e)ine (> 12.7 nmol/mL)
Trial: 8091435
Drug: High plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High plasma levels of homocyst(e)ine (> 12.7 nmol/mL) in normotensive subjects
Trial: 8091435
Drug: High plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High plasma levels of homocyst(e)ine (> 12.7 nmol/mL) in men 60 years or younger
Trial: 3053207
Drug: cisplatin 100
RxNorm normalized name: CISPLATIN 100MG/VIL (PF) INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cisplatin 100 mg/m2 with cyclophosphamide 600 mg/m2
Trial: 3053207
Drug: carboplatin 300
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: carboplatin 300 mg/m2 with cyclophosphamide 600 mg/m2
Trial: 3053207
Drug: iproplatin 240
RxNorm normalized name: Aroplatin
DrugBank: Aroplatin (DB17319)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iproplatin 240 mg/m2 with cyclophosphamide 600 mg/m2
Trial: 3053207
Drug: cyclophosphamide/CHIP combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cyclophosphamide/CHIP combination
Trial: 3053207
Drug: cyclophosphamide/CBDCA combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cyclophosphamide/CBDCA combination
Trial: 15762943
Drug: Solving doubles
RxNorm normalized name: Solv X
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solving doubles problems (e.g., 2 + 2 = ?)
Trial: 12168783
Drug: Hyaluronic acid
RxNorm normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hyaluronic acid gel (HA gel)
Trial: 8564096
Drug: Prednisolone (0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone (0.6 mg/kg/d)
Trial: 2405996
Drug: Improved sanctuary
RxNorm normalized name: Improvest
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Improved sanctuary therapy
Trial: 2694853
Drug: Shortening of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shortening of therapy duration
Trial: 2405996
Drug: Salvage of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salvage of relapsed patients with better chemotherapy regimens
Trial: 2405996
Drug: Detection of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Detection of drug‐resistant clones of cells
Trial: 2694853
Drug: Delivery of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delivery of optimum therapy and supportive care
Trial: 7238342
Drug: Intratracheal administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intratracheal administration of gentamicin (40 mg, undiluted, 6-hourly)
Trial: 26308176
Drug: favipiravir 1,200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: favipiravir 1,200 mg
Trial: 26308176
Drug: favipiravir 2,400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: favipiravir 2,400 mg
Trial: 19826060
Drug: moxifloxacin 400
RxNorm normalized name: moxifloxacin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: moxifloxacin 400 mg
Trial: 23304688
Drug: Immediate loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate loading of single implants (non-occlusal temporary crown within 24 hours)
Trial: 23304688
Drug: Delayed loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed loading of single implants (definitive crown 4 to 5 months later)
Trial: 19477488
Drug: Aspirin 100
RxNorm normalized name: aspirin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 100 mg/day for 3 months
Trial: 16094585
Drug: Intravenous tramadol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous tramadol 50 mg
Trial: 7660438
Drug: Oral iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral iron (60mg elemental iron per day)
Trial: 2468963
Drug: Higher daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher daily dosages of enalapril (40 mg and, when necessary, 60 mg)
Trial: 2468963
Drug: 20 mg/day
RxNorm normalized name: futibatinib 20 mg/day (4 mg x 5) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg/day enalapril and hydrochlorothiazide (25 mg/day and, when necessary, 50 mg)
Trial: 544571
Drug: Pelvic irradiation
RxNorm normalized name: Sus scrofa renal pelvis preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pelvic irradiation alone or followed by chlorambucil therapy.
Trial: 21196929
Drug: Sertraline (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline (100 mg/day)
Trial: 19169146
Drug: Propofol in
RxNorm normalized name: propofol Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol in combination with meperidine
Trial: 16368051
Drug: Orlistat 120
RxNorm normalized name: orlistat 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orlistat 120 mg three times a day (O group)
Trial: 16368051
Drug: Micronised fenofibrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micronised fenofibrate 200 mg/day (F group)
Trial: 16368051
Drug: Orlistat 120
RxNorm normalized name: orlistat 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orlistat 120 mg tid plus micronised fenofibrate 200 mg/day (OF group)
Trial: 12507240
Drug: HA‐coated threaded
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HA‐coated threaded implants
Trial: 14696659
Drug: TPS implants
RxNorm normalized name: OTX-TP
DrugBank: Travoprost (DB00287)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: TPS implants
Trial: 2713216
Drug: Dextromethorphan (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextromethorphan (120 mg orally)
Trial: 11368483
Drug: Johnstone pressure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Johnstone pressure splints (JPSs) combined with Bobath's neurodevelopmental therapy (NDT)
Trial: 26896345
Drug: Dexmedetomidine 12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine 12.5 μg/kg (D12.5)
Trial: 26896345
Drug: Dexmedetomidine 25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine 25 μg/kg (D25)
Trial: 26896345
Drug: Dexmedetomidine 25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine 25 μg/kg and MK‐467 600 μg/kg (D25M600)
Trial: 26896345
Drug: MK‐467 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK‐467 300 μg/kg (M300)
Trial: 17272731
Drug: Low-dose prophylactic
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose prophylactic haloperidol treatment
Trial: 12433233
Drug: bupropion SR
RxNorm normalized name: Bupropion Hydrochloride 100 MG Oral Tablet, Extended Release, 12 HR [BUPROPION SR]
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: bupropion SR (150 mg for week 1, 300 mg for weeks 2 to 5)
Trial: 10453828
Drug: Misoprostol 50
RxNorm normalized name: diclofenac-misoprostol 50 mg-200 mcg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Misoprostol 50 microg four hourly (to a maximum of four doses)
Trial: 10453828
Drug: Dinoprostone gel
RxNorm normalized name: Dinoprostone
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dinoprostone gel 1 mg six hourly (to a maximum of three doses)
Trial: 2199281
Drug: Insulin analogues
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin analogues (B9Asp + B27Glu or B10Asp)
Trial: 30838777
Drug: Statistical testing
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statistical testing strategies for treatment efficacy in marker-positive subpopulations
Trial: 30838777
Drug: Statistical testing
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statistical testing strategies for treatment efficacy in marker-negative patients
Trial: 30838777
Drug: Statistical testing
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statistical testing strategies based on probabilities of asserting treatment efficacy
Trial: 17616452
Drug: Telmisartan (TS)
RxNorm normalized name: Telmisartan
DrugBank: Telmisartan (DB00966)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Telmisartan (TS) 40 mg/day p.o.
Trial: 11158473
Drug: Cys‐LT receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cys‐LT receptor antagonists (Cys‐LTRA) such as montelukast
Trial: 30283029
Drug: Ketamine 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine 0.1 mg/kg
Trial: 7930028
Drug: Piroximone infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Piroximone infusion at 5 micrograms/kg/min
Trial: 7930028
Drug: Piroximone infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Piroximone infusion at 10 micrograms/kg/min
Trial: 3276999
Drug: Buprenorphine 2
RxNorm normalized name: buprenorphine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine 2 mg (n = 10)
Trial: 3276999
Drug: Buprenorphine 4
RxNorm normalized name: buprenorphine 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine 4 mg (n = 4)
Trial: 3276999
Drug: Buprenorphine 8
RxNorm normalized name: buprenorphine 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine 8 mg (n = 2)
Trial: 31247017
Drug: Laughter therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laughter therapy (4 sessions, once every two weeks for seven weeks)
Trial: 28325221
Drug: Individualized homeopathic
RxNorm normalized name: Urtica urens homeopathic preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individualized homeopathic treatment (IHT)
Trial: 25897569
Drug: 8-hour nightly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8-hour nightly CPAP treatment
Trial: 23732713
Drug: Aspirin (n
RxNorm normalized name: ACETAMINOPHEN 250 mg / ASPIRIN 250 mg / CAFFEINE 65 mg ORAL TABLET, FILM COATED [EXCEDRIN MIGRAINE acetaminophen, aspirin (nsaid) and caffeine]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (n = 386)
Trial: 23732713
Drug: Composite of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Composite of all VTE and clinically significant bleeding events (Aspirin vs Dalteparin)
Trial: 16865013
Drug: dorzolamide 1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dorzolamide 1% 3 times daily
Trial: 16865013
Drug: carteolol hydrochloride
RxNorm normalized name: Carteolol Hydrochloride
DrugBank: Carteolol (DB00521)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: carteolol hydrochloride 2% twice daily
Trial: 16865013
Drug: latanoprost-dorzolamide combination
RxNorm normalized name: latanoprost and dorzolamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: latanoprost-dorzolamide combination
Trial: 16865013
Drug: latanoprost-carteolol combination
RxNorm normalized name: carteolol, combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: latanoprost-carteolol combination
Trial: 12627729
Drug: Sodium oxybate
RxNorm normalized name: Sodium Oxybate
DrugBank: Sodium oxybate (DB09072)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium oxybate (6 g nightly, adjustable between 3 to 9 g)
Trial: 3296628
Drug: High protein
RxNorm normalized name: Vital High Protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High protein intake (3‐5 g/kg bw for 24 h)
Trial: 3296628
Drug: Uncontrolled protein
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Uncontrolled protein intake (2‐2.5 g/kg bw)
Trial: 3296628
Drug: Low protein
RxNorm normalized name: Low protein mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low protein intake (1.2 g/kg bw for 12 days)
Trial: 29703287
Drug: Intracameral combination
RxNorm normalized name: bimatoprost
DrugBank: Bimatoprost (DB00905)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intracameral combination of 2 mydriatics and 1 anesthetic (Mydrane)
Trial: 29703287
Drug: Topical regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical regimen (control group)
Trial: 20586697
Drug: Behavioral interventions
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Behavioral interventions (group and individual treatment, dietary counseling, cognitive-behavioral therapy)
Trial: 20586697
Drug: Pharmacologic strategies
RxNorm normalized name: COPD pharmacologic substance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacologic strategies (metformin, fenfluramine, sibutramine, topiramate, reboxetine)
Trial: 16888042
Drug: Overtrained group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overtrained group (OT) performing 10 x 1 at 100% 1 RM daily for 2 weeks
Trial: 11822985
Drug: Current chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Current chemotherapy approaches
Trial: 11798658
Drug: Nifedipine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (10 mg tid)
Trial: 14468
Drug: Atenolol (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol (600 mg daily)
Trial: 14468
Drug: Bendrofluazide (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bendrofluazide (15 mg daily)
Trial: 26843155
Drug: Lipid-based nutrient
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipid-based nutrient supplements (SQ-LNSs)
Trial: 21737178
Drug: CHG gel
RxNorm normalized name: CHG Teat Dip
DrugBank: Isopropyl alcohol (DB02325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHG gel
Trial: 19346443
Drug: GTN (0.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GTN (0.8 mg)
Trial: 19346443
Drug: PETN (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PETN (80 mg)
Trial: 19346443
Drug: GTN plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GTN plus LA (600 mg)
Trial: 17688053
Drug: Fibrin glue
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fibrin glue injection after aspiration of more than 15 ml of CSF (Group A)
Trial: 17688053
Drug: Fibrin glue
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fibrin glue injection without CSF aspiration (Group B)
Trial: 9718197
Drug: Inhaled glucocorticoids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled glucocorticoids (beclomethasone or budesonide) > or = 1500 microg/day for at least 12 months
Trial: 9718197
Drug: Prior oral
RxNorm normalized name: Priorix
DrugBank: Rubella virus vaccine (DB10317)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prior oral glucocorticoid exposure (OG)
Trial: 9718197
Drug: Inhaled glucocorticoids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled glucocorticoids (IG)
Trial: 9718197
Drug: High-dose IG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose IG
Trial: 776209
Drug: PGE2 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PGE2 1.0 mg
Trial: 776209
Drug: PGE2 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PGE2 1.5 mg
Trial: 776209
Drug: PGE2 2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PGE2 2.0 mg
Trial: 776209
Drug: PGE2 3.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PGE2 3.0 mg
Trial: 776209
Drug: PGF2alpha 10.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PGF2alpha 10.0 mg
Trial: 24851793
Drug: Single preoperative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single preoperative dose of pregabalin combined with a COX‐2 inhibitor
Trial: 24851793
Drug: COX‐2 inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COX‐2 inhibitor only (Control)
Trial: 23146926
Drug: Ivabradine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ivabradine (10 mg)
Trial: 23146926
Drug: Beta-blockers (bisoprolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-blockers (bisoprolol 2.5 mg/day, carvedilol 12.5 mg/day, atenolol 50 mg/day)
Trial: 19223709
Drug: Gelatin solutions
RxNorm normalized name: Gelatin
DrugBank: Gelatin (DB11242)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gelatin solutions
Trial: 17122576
Drug: Midazolam (loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (loading dose of 1 mg followed by continuous infusion of 0.5 mg/h)
Trial: 15098969
Drug: Topical retinoids
RxNorm normalized name: tocopheryl retinoate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical retinoids and antibiotics combination therapy